Paid Clinical Trials Augusta
Discover 155 paid clinical trials in Augusta, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
CDK4/6 InhibitorThe CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Sponsor:
American Society of Clinical Oncology
Location:
Code:
NCT06377852
Conditions
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 65+
Healthy Volunteers: Not accepted
Interventions
Palbociclib 125mg
Ribociclib 600mg
Ribociclib
Palbociclib
RavulizumabStudy of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
Targeted TherapyTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05564377
Conditions
Advanced Malignant Solid Neoplasm
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Malignant Solid Neoplasm
Malignant Female Reproductive System Neoplasm
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Alpelisib
Binimetinib
Biopsy Procedure
Biospecimen Collection
Bone Marrow Aspiration
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Ipatasertib & Megestrol AcetateTesting the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05538897
Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Metastatic Endometrial Endometrioid Adenocarcinoma
Recurrent Endometrial Endometrioid Adenocarcinoma
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Ipatasertib
Magnetic Resonance Imaging
Megestrol Acetate
Nivolumab & IpilimumabA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT02339571
Conditions
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Echocardiography Test
Ipilimumab
Magnetic Resonance Elastography
Selumetinib & OlaparibTesting the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05554328
Conditions
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy Procedure
Biospecimen Collection
Bone Marrow Aspiration and Biopsy
Computed Tomography
Echocardiography Test
Observational StudyPrevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Sponsor:
Ensoma
Location:
Code:
NCT06605378
Conditions
Chronic Granulomatous Disease (CGD)
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Venetoclax & ObinutuzumabTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04269902
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Obinutuzumab